Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | BRAF | P15056 | 5/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 3/20 | 0.46 |
| ▸ | BCR | P11274 | 3/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.46 |
| ▸ | LCK | P06239 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544589 | 0.91 | ABL1 (0.55) | BRAFABL1BCRKITLCK | |
| SCHEMBL543731 | 0.88 | BRAF (0.51) | BRAFABL1BCRKITDDR1 | |
| SCHEMBL544655 | 0.85 | KCNQ3 (0.47) | BRAFABL1BCRKITKDR | |
| SCHEMBL543623 | 0.81 | BRAF (0.54) | BRAFABL1BCRKDRPDGFRB | |
| SCHEMBL544048 | 0.80 | MAPK14 (0.46) | ABL1BCRKDRPDGFRBPDGFRA | |
| SCHEMBL2828692 | 0.79 | FLT1 (0.49) | SMN1; SMN2KITLCKKDRNPC1 | |
| SCHEMBL543696 | 0.79 | MAPK14 (0.46) | ABL1BCRKITPDGFRBPDGFRA | |
| SCHEMBL544093 | 0.79 | MEN1 (0.50) | SMN1; SMN2ABL1BCRKDRPDGFRB | |
| SCHEMBL544504 | 0.79 | ABL1 (0.58) | ABL1BCRKITKDRPDGFRB | |
| SCHEMBL543637 | 0.78 | FLT1 (0.44) | KITKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | claimed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| EP-2117531-B1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2016-11-02 | — | — | EP | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-8227470-B2 | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors | AB SCIENCE (FR) | 2012-07-24 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE | 2010-04-15 | — | — | US | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | AB SCIENCE | 2008-08-28 | — | — | US | disclosed |
| WO-2008084103-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | AB SCIENCE (FR) | 2008-07-17 | — | — | WO | disclosed |
| WO-2007026251-A2 | USE OF DUAL C-KIT/FGFR3 INHIBITORS FOR TREATING MULTIPLE MYELOMA | AB SCIENCE (FR) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207572-A1 | Use of Dual C-Kit/Fgfr3 Inhibitors for Treating Multiple Myeloma | KIT, FGFR3, AURKC | SMN1; SMN2 3895/4885BRAF 710/4885DGAT1 4690/4885 |
| US-20100093750-A1 | COMBINATION TREATMENT OF SOLID CANCERS WITH ANTIMETABOLITES AND TYROSINE KINASE INHIBITORS | ERBB2, ERBB3, ERBB4 | SMN1; SMN2 2836/4885BRAF 216/4885DGAT1 2112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.